Clinical (structural/functional monitoring) · PMID 39569781
Objective structural and functional monitoring of polypeptide retinal neuroprotective therapy in diabetic retinopathy — VialBase Research
Most recent DR evidence; demonstrates objective (not just subjective) monitoring of benefit. Cited in the clinical-evidence table.
Last updated · 2024 · Malakhova AI et al. · Vestn Oftalmol
Key findings
- Used objective structural and functional measures to monitor polypeptide retinal neuroprotective therapy in diabetic retinopathy
- Confirmed measurable structural and functional benefit in the treated cohort
- The most recent indexed diabetic-retinopathy study in this class (2024)
Objective monitoring of retinal neuroprotective therapy in DR (PMID: 39569781)
Summary
This 2024 study applied objective structural and functional monitoring to polypeptide retinal neuroprotective therapy in diabetic retinopathy, confirming measurable benefit and giving the DR use case its most recent, objectively-measured support.
Relevance
The freshest diabetic-retinopathy evidence for the Retinalamin class, and notable for using objective endpoints. Names the “polypeptide retinal neuroprotective therapy” category; still Russian clinical practice, no Western RCT.
See Also
- Parent compound: Retinalamin